The European Commission (EC) has approved bevacizumab (Avastin, Genentech/Roche)in combination with standard chemotherapy (carboplatin and gemcitabine) as a treatment for women with first recurrence of platinum-sensitive ovarian cancer.
Bevacizumab is already approved by the EC as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. The additional approval of the medicine is important for women with ovarian cancer who are now able to…Continue
Added by Peter Hofland, PhD on October 31, 2012 at 1:00am — No Comments
Earlier this week the first patient has been dosed in a Phase Ib/IIa study of CRLX101 (formerly called IT-101, Cerulean Pharma Inc.), dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha, in combination with bevacizumab (Avastin®, Genentech/Roche) in metastatic renal cell carcinoma (mRCC) patients. Cerulean also announced the completion of enrollment of its randomized Phase II study in advanced non-small…Continue
Added by Peter Hofland, PhD on July 2, 2012 at 7:00pm — No Comments
The U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted orphan drug designation for VAL-083 for the treatment of glioma, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
Of the estimated 17,000 primary brain tumors diagnosed in the United States each year, approximately 60% are gliomas. Attention was drawn to this form of brain cancer when Senator Ted Kennedy was…
Added by Peter Hofland, PhD on February 15, 2012 at 10:30pm — No Comments
The European Commission has approved bevacizumab (Avastin®, Roche) in combination with standard chemotherapy (carboplatin and paclitaxel) as a first-line treatment following surgery for women with advanced ovarian…Continue
Added by Peter Hofland, PhD on December 23, 2011 at 10:00am — No Comments
The U.S. Food and Drug Administration (FDA) today authorized Circadian Technologies Ltd. to initiate clinical trials with its investigational new drug VGX-100. The first Phase I trials will study VGX-100 in patients with a variety of late stage cancers.
VGX-100 is a fully human antibody that acts against the human VEGF-C protein. Treatment for…
Added by Peter Hofland, PhD on October 31, 2011 at 7:00am — No Comments
Added by Peter Hofland, PhD on September 23, 2011 at 12:30am — No Comments
Added by Peter Hofland, PhD on June 5, 2011 at 6:00pm — No Comments
Added by Peter Hofland, PhD on June 3, 2011 at 3:30pm — No Comments
Added by Peter Hofland, PhD on April 15, 2011 at 4:00pm — No Comments
Added by Peter Hofland, PhD on February 8, 2011 at 11:30am — No Comments
The world's largest online community for physicians, Sermo, announced the publication of a free report about physicians’ reaction to the FDA decision to rescind the indication for bevacizumab (Avastin®, Genentech) in the treatment of breast cancer. The report titled 'Should Avastin…Continue
Added by Peter Hofland, PhD on February 4, 2011 at 7:00am — No Comments
Every year more than 146,000 Americans are diagnosed with colorectal cancer , the third most common type of cancer in the United States. It also is the third highest cause of cancer death, killing nearly 50,000 people annually, more than who die each year on the nation’s roadways. This cancer affects men and women in nearly equal numbers.
In patients with stage III colon cancer who have undergone complete resection of the primary tumor or for palliative…
Bevacizumab (Avastin®, Genentech/Roche) in combination with paclitaxel remains a treatment option for women with breast cancer, but not with other combinations. Earlier today the European Medicines Agency (EMA) confirmed that the benefits of bevacizumab in combination with paclitaxel outweigh its risks and that this combination remains a valuable treatment option for patients suffering from metastatic breast cancer.
The decision by the European regulators…
Added by Peter Hofland, PhD on December 16, 2010 at 10:00am — No Comments
The U.S. Food and Drug Administration (FDA) announced today that the agency is recommending removing the breast cancer indication from the label for bevacizumab (Avastin®, Genentech/Roche) because the drug has not been shown to be safe and effective for that use.
The FDA is making this recommendation after reviewing the results of four clinical studies of bevacizumab in women with HER2-negative, metastatic…
Added by Peter Hofland, PhD on December 16, 2010 at 9:30am — No Comments
Added by Peter Hofland, PhD on October 11, 2010 at 6:30am — No Comments
Added by Peter Hofland, PhD on September 1, 2010 at 9:30am — No Comments
Added by Peter Hofland, PhD on June 6, 2010 at 11:30am — No Comments
Added by Peter Hofland, PhD on November 20, 2009 at 7:00pm — No Comments